To include your compound in the COVID-19 Resource Center, submit it here.

Remicade infliximab: Marketed

In the double-blind North American and European Phase III ASPIRE study in 1049 patients, 3 and 6 mg/kg doses of Remicade plus methotrexate (MTX) met the 3 co-primary endpoints compared to MTX alone at week

Read the full 354 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE